Recombinant HIV-1 virus with the indicated mutations in the protease gene. Mutations have been reported from drug resistant viral variants emerging in vivo, e.g. after treatment with the HIV protease inhibitor saquinavir
Simply ask us !One of the most interesting features of EVAg's catalogue is its flexibility, please do not hesitate to contact us by using our contact form. We can add to the catalogue tailor-made products on demand, as well as access to plateforms, or services. With the large panel of virology laboratories in our consortium, there are good chances that we would have what you are looking for.